A NEW CLASS OF DRUG CARRIERS FOR TREATMENT OF MS

用于治疗多发性硬化症的新型药物载体

• 批准号: 6311389
• 负责人: KENNETH M KOSAK
• 金额: $ 13.58万
• 依托单位: KK BIOMED CORPORATION
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-04-15 至 2002-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6311389
• 关键词: T lymphocyte; bioengineering /biomedical engineering; cell line; cyclodextrins; cyclosporines; drug adverse effect; drug delivery systems; drug design /synthesis /production; drug screening /evaluation; extended care; fluorescence; gel filtration chromatography; high performance liquid chromatography; laboratory rat; macromolecule; mitoxantrone; multiple sclerosis; nervous system disorder chemotherapy; neuropharmacologic agent; pharmacokinetics; pharmacology; polymers; tissue /cell culture

DESCRIPTION (adapted from applicant's abstract): A patented, new class of drug carriers comprised of polymerized cyclodextrin (polyCD) will be synthesized and characterized for the treatment of MS. The carrier will provide a macromolecular delivery system through entrapment of the drug without conjugation. This can reduce side effects and increase bioavailability of drug. The carrier is designed to biodegrade arid release drug within the cell. The expected advantages are: (1) It will allow the use of drugs designed solely for efficacy without conjugation requirements. (2) It will allow the use of drugs designed solely for efficacy without regard for solubility. (3) Unconjugated drugs can be delivered as macromolecules and released within the T cell. (4) Drugs can be targeted by coupling the carrier to biorecognition molecules. These are advantages not currently available for treatment of MS. Two carriers will be synthesized and compared for efficacy. One will have mitoxantrone and the other cyclosporin an entrapped within it. The drug-loaded carriers will be purified by gel chromatography. The carrying capacity, stability, release activity, and T cell inhibition in vitro of each drug-loaded carrier will be characterized. PROPOSED COMMERCIAL APPLICATION: Polymerized cyclodextrin drug carriers can expand long-term treatment options for MS. Other markets include cancer treatment as well as treatment for many infectious diseases.

描述（改编自申请人的摘要）：专利的新药物 由聚合环糊精（polyCD）组成的载体将合成，并 用于治疗MS的特征。运营商将提供 大分子递送系统通过无需包裹 共轭。这可以减少副作用并增加药物的生物利用度。 该载体旨在在细胞内生物降解干旱释放药物。这 预期优势是： （1）它将允许使用仅用于功效的药物而无需使用 共轭要求。 （2）它将允许使用仅用于功效的药物而无需考虑 用于溶解度。 （3）未结合的药物可以作为大分子输送并在内释放 T细胞。 （4）可以通过将载体与生物识别分子耦合来靶向药物。 这些是当前无法用于治疗MS的优点。 将合成两个载体并比较功效。一个人会 Mitoxantrone和另一个缠绕在其内部的环孢菌素。加载了药物 载体将通过凝胶色谱纯化。承载能力， 每个药物的稳定性，释放活性和T细胞的体外抑制 载体将被描述。 拟议的商业应用： 聚合环糊精药物载体可以扩大MS的长期治疗选择。 其他市场包括癌症治疗以及许多传染病的治疗。